Bayer acquires remaining 25% stake in Bayer Zydus Pharma

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market, said the company in a release.

Pharma majors Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited (formerly Cadila Healthcare) on May 2 announced the conclusion of their joint venture (JV) - Bayer Zydus Pharma Private Limited (BZPPL). The announcement came after Bayer acquired the remaining 25 percent stake in Bayer Zydus Pharma to secure full ownership.

The 50:50 joint venture was established on January 28, 2011, for the sales and marketing of pharmaceutical products in India. Bayer is now securing full ownership of the entity, as per pre-agreed JV terms.

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market, said the company in a release.

"It combined Zydus's strong Indian marketing, sales expertise, wide distribution reach and rich industry network, with Bayer’s global expertise in commercializing novel products and bringing in innovation to India. BZPPL made remarkable strides in various therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology, and oncology."

Shweta Rai, Managing Director - India and Country Division Head - South Asia, Bayer's Pharmaceuticals division, said, “Zydus Lifesciences has been a formidable partner in our joint mission towards introducing best-in-class innovative health solutions and addressing the unmet healthcare needs of patients in India. As we assume full ownership of BZPPL, Bayer remains committed to ensuring its steadfast presence in India. Building on the gains made over more than a decade, we aim to carry forward our mission of ‘Health for All, Hunger for None’."

Bayer is a global enterprise in the life science fields of health care and nutrition. In 2023, the group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.